Climb Bio

Climb Bio News

News

0

Ticker

CLYM

ISIN

US28658R1068

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE News Documents

Climb Bio Eulerpool News

Climb Bio Stock News

Climb Bio is being monitored by journalists and investors worldwide. We gather the latest Climb Bio news here.

Climb Bio Stock Press Releases

Climb Bio regularly publishes news on the company's website that are relevant for investors.

Climb Bio News 2026

This page contains all current news, analysis and press releases for Climb Bio stock (CLYM, ISIN: US28658R1068). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at Climb Bio.

Climb Bio Stock

Climb Bio Eliem Therapeutics, Inc. develops novel therapies for neuronal excitability disorders, targeting unmet needs in psychiatry, epilepsy, chronic pain, and nervous system disorders. Its lead product ETX-123, a Kv7.2/3 potassium channel opener, is designed to improve safety and tolerability over earlier molecules while leveraging clinically validated mechanisms. The company focuses on validated mechanisms of action with therapeutic potential for patients with these conditions. ETX-123 is a generate new chemical entities candidate that harnesses the efficacy of Kv7.2/3 channel mechanism, with encouraging clinical data in depression, epilepsy, and pain. The company's pipeline includes clinically differentiated product candidates targeting validated therapeutic targets to deliver improved therapeutics. Eliem Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Wilmington, Delaware, with 30 full-time employees. The company's revenue model is not disclosed in the business description, as it is a clinical-stage biotechnology firm focused on research and development rather than commercial product sales. Its primary focus is on advancing its pipeline through clinical trials to achieve regulatory approvals and potential future partnerships or sales.